ClinicalTrials.gg
CompletedNCT05276063LIDSUpdated Sep 23, 2026Results posted

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

A Phase 2/3 interventional study of Linsitinib and Placebo in Thyroid Eye Disease, Graves Orbitopathy and Endocrine System Diseases, sponsored by Sling Therapeutics, Inc.. Completed at 30 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Sling Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Enrollment
19th of 47
90 · median 84
Started
2022
with 4 others
Phase 2/3
3 of 53
1 open now
Registered
18th of 53
by date
Lead sponsor
3 of 53
Sling Therapeutics, Inc.

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 19th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2/3, and was the 18th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

03

Conditions studied

  • Thyroid Eye Disease
  • Graves Orbitopathy
  • Endocrine System Diseases
  • Eye Diseases
  • Thyroid Associated Ophthalmopathy
  • Graves Ophthalmopathy
  • Thyroid Diseases
  • Orbital Diseases
  • Proptosis
  • IGF1R
  • Exophthalmos
  • Hashimoto

Keywords

  • Thyroid Associated Ophthalmopathies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Graves' Disease and/or Hashimoto's thyroiditis associated with active moderate to severe TED with a CAS ≥ 4 (on the 7- item scale) for the most severely affected eye (primary study eye) at Screening and Baseline
  • Confirmed active TED (not sight-threatening but has an appreciable impact on daily life, with onset (as determined by patient records) within 12 months prior to the Baseline visit and usually associated with one or more of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal for race and gender, and/or inconstant or constant diplopia.
  • Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine levels [FT3] \< 50% above or below the normal limits) at Screening.
  • Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Screening and is not planning for any such treatment during the course of the study.

Exclusion criteria

Exclusion Criteria:

  • Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months.
  • Corneal decompensation unresponsive to medical management.
  • Previous orbital irradiation or orbital surgery.
  • Any use (intravenous [IV] or oral) with a cumulative dose equivalent to >= 1g of methylprednisolone or equivalent for the treatment of TED within 3 months of Screening.
  • Prior IGF-1R inhibitor therapy for any condition.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo Arm

    Drug: Placebo

  • Active comparator
    Low Dose

    Active Arm Low Dose Linsitinib

    Drug: Linsitinib

  • Active comparator
    High Dose

    Active Arm High Dose Linsitinib

    Drug: Linsitinib

Interventions

  • Study medication taken twice daily by mouth

  • DrugPlacebo

    Placebo taken twice daily by mouth

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Are Proptosis Responders at Week 24

    Proptosis response is defined as a ≥ 2 mm reduction from Baseline in the primary study eye without deterioration (≥ 2 mm increase) of proptosis in the contralateral non-study eye.

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of Subjects Who Are Overall Responders at Week 24

    Overall response is defined as a \>= 2-point reduction from baseline CAS and \>= 2 mm reduction in proptosis in the primary study eye at week 24 without deterioration (\>= 2-point increase) in CAS or deterioration (\>= 2 mm increase) of proptosis in the contralateral non-study eye. In the event of death, the latest CAS/proptosis observations will be carried forward. Missing values of CAS and proptosis measurement in the primary study eye and contralateral non-study eye at week 24 are multiple imputed by using all available prior CAS/proptosis measures, smoking status and treatment group.

    Time frame: 24 weeks

  2. Percentage of Subjects With a CAS Value of 0 or 1 at Week 24

    A CAS value of 0 or 1 in primary study eye at week 24. In the event of death, the latest CAS observation will be carried forward. Missing values of CAS at week 24 are multiple imputed by using all available prior CAS measures, smoking status and treatment group

    Time frame: 24 weeks

  3. Change From Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24.

    Change from baseline to week 24 in Graves' Ophthalmology Quality of Life (GO-QoL) overall score or to last assessed value in case of death. Missing values of GO-QoL overall score up to week 24 are multiple imputed by using all available prior GO-QoL overall score measures, smoking status and treatment group. Overall scale was measured from 0 minimum to 100 maximum (0 is worse health state and 100 is best health state)

    Time frame: 24 weeks

07

Results

Posted Aug 26, 2026

Participant flow

Participants were recruited at investigative clinic sites and through central recruitment.

Participant flow — Overall Study
MilestonePlacebo BID75 mg BID150 mg BID
Started303030
Completed222322
Not completed878

Outcome measures

PrimaryPercentage of Subjects Who Are Proptosis Responders at Week 24

Proptosis response is defined as a ≥ 2 mm reduction from Baseline in the primary study eye without deterioration (≥ 2 mm increase) of proptosis in the contralateral non-study eye.

Time frame:
24 weeks
Reported as:
Number · % of participants
Percentage of Subjects Who Are Proptosis Responders at Week 24
% of participantsPlacebo BID75 mg BID150 mg BID
Percentage of Subjects Who Are Proptosis Responders at Week 2418.838.951.7
Statistical analysis
  • Placebo BID vs 150 mg BID · Cochran-Mantel-Haenszel · p = 0.01 · Risk difference (rd): 0.345 · 95% CI 0.098 to 0.593stratified by smoking status at a one-sided significance level alpha = 2.5%
  • Placebo BID vs 75 mg BID · Cochran-Mantel-Haenszel · p = 0.090 · Risk difference (rd): 0.217 · 95% CI -0.040 to 0.475stratified by smoking status at a one-sided significance level alpha = 2.5%
SecondaryPercentage of Subjects Who Are Overall Responders at Week 24

Overall response is defined as a \>= 2-point reduction from baseline CAS and \>= 2 mm reduction in proptosis in the primary study eye at week 24 without deterioration (\>= 2-point increase) in CAS or deterioration (\>= 2 mm increase) of proptosis in the contralateral non-study eye. In the event of death, the latest CAS/proptosis observations will be carried forward. Missing values of CAS and proptosis measurement in the primary study eye and contralateral non-study eye at week 24 are multiple imputed by using all available prior CAS/proptosis measures, smoking status and treatment group.

Time frame:
24 weeks
Reported as:
Number · % of participants
Percentage of Subjects Who Are Overall Responders at Week 24
% of participantsPlacebo BID75 mg BID150 mg BID
Percentage of Subjects Who Are Overall Responders at Week 2418.537.350.2
Statistical analysis
  • Placebo BID vs 150 mg BID · Cochran-Mantel-Haenszel · p = 0.013 · Risk difference (rd): 0.334 · 95% CI 0.087 to 0.581Stratified by smoking status at a one-sided significance level alpha = 2.5%
  • Placebo BID vs 75 mg BID · Cochran-Mantel-Haenszel · p = 0.105 · Risk difference (rd): 0.204 · 95% CI -0.050 to 0.459Stratified by smoking status at a one-sided significance level alpha = 2.5%.
SecondaryPercentage of Subjects With a CAS Value of 0 or 1 at Week 24

A CAS value of 0 or 1 in primary study eye at week 24. In the event of death, the latest CAS observation will be carried forward. Missing values of CAS at week 24 are multiple imputed by using all available prior CAS measures, smoking status and treatment group

Time frame:
24 weeks
Reported as:
Number · % of participants
Percentage of Subjects With a CAS Value of 0 or 1 at Week 24
% of participantsPlacebo BID75 mg BID150 mg BID
Percentage of Subjects With a CAS Value of 0 or 1 at Week 2435.147.756.8
Statistical analysis
  • Placebo BID vs 150 mg BID · Cochran-Mantel-Haenszel · p = 0.204 · Risk difference (rd): 0.179 · 95% CI -0.093 to 0.451Stratified by smoking status at a one-sided significance level alpha = 2.5%.
  • Placebo BID vs 75 mg BID · Cochran-Mantel-Haenszel · p = 0.146 · Risk difference (rd): 0.201 · 95% CI -0.059 to 0.460Stratified by smoking status at a one-sided significance level alpha = 2.5%.
SecondaryChange From Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24.

Change from baseline to week 24 in Graves' Ophthalmology Quality of Life (GO-QoL) overall score or to last assessed value in case of death. Missing values of GO-QoL overall score up to week 24 are multiple imputed by using all available prior GO-QoL overall score measures, smoking status and treatment group. Overall scale was measured from 0 minimum to 100 maximum (0 is worse health state and 100 is best health state)

Time frame:
24 weeks
Reported as:
Least squares mean · Score on Scale
Change From Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24.
Score on ScalePlacebo BID75 mg BID150 mg BID
Change From Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24.0.488 ± 2.6996.387 ± 2.63311.264 ± 3.057
Statistical analysis
  • Placebo BID vs 150 mg BID · Mixed Models Analysis · p = 0.002 · Mean difference (final values): 10.776 · 95% CI 3.418 to 18.135Model uses change in GO-QoL as outcome and covariates: treatment, visit, interactions, baseline GO-QoL, smoking status.
  • Placebo BID vs 75 mg BID · Mixed Models Analysis · p = 0.057 · Mean difference (final values): 5.899 · 95% CI -1.411 to 13.210

Adverse events

Collected over Adverse events were collected from time of signed informed consent through week 120 follow up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/31 (0%)1/31 (3.2%)9/31 (29%)
75 mg BID0/30 (0%)0/30 (0%)14/30 (46.7%)
150 mg BID0/29 (0%)2/29 (6.9%)18/29 (62.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo75 mg BID150 mg BID
Electrocardiogram T Wave AbnormalInvestigations0/310/301/29
Guillain-Barre SyndromeNervous system disorders0/310/301/29
Pericardial EffusionCardiac disorders1/310/300/29
Pleural EffusionRespiratory, thoracic and mediastinal disorders1/310/300/29
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo75 mg BID150 mg BID
DiarrheaGastrointestinal disorders2/314/306/29
NauseaGastrointestinal disorders1/313/306/29
HeadacheNervous system disorders1/313/306/29
FatigueGeneral disorders2/316/305/29
ALT IncreasedInvestigations0/313/304/29
HyperhidrosisSkin and subcutaneous tissue disorders0/311/304/29
Muscle SpasmsMusculoskeletal and connective tissue disorders1/312/303/29
AST IncreasedInvestigations0/312/303/29
AlopeciaSkin and subcutaneous tissue disorders0/313/300/29
DizzinessNervous system disorders3/310/302/29

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo BID75 mg BID150 mg BIDTotal
Mean50.9 ± 12.7052.8 ± 11.2550.1 ± 14.2951.3 ± 12.71
Sex: Female, Male
Sex: Female, Male(Participants)Placebo BID75 mg BID150 mg BIDTotal
Female17192157
Male1311933
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo BID75 mg BID150 mg BIDTotal
American Indian or Alaska Native0000
Asian2147
Native Hawaiian or Other Pacific Islander0000
Black or African American2338
White26252374
More than one race0000
Unknown or Not Reported0101
08

Study locations

30 sites
  • Thrive Health Research
    Beverly Hills, California 90210, United States
  • UC San Diego Health
    La Jolla, California 92093, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Byers Eye Institute - Stanford University
    Palo Alto, California 94303, United States
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
  • Center for Excellence in Eye Care
    Miami, Florida 33176, United States
  • Sarasota Retina Institute
    Sarasota, Florida 34239, United States
  • Chicago Oculofacial Plastic Surgery
    Chicago, Illinois 60614, United States
  • Wolfe Eye Clinic
    West Des Moines, Iowa 50266, United States
  • Mass Eye and Ear
    Boston, Massachusetts 02114, United States
  • Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • Kahana Oculoplastic & Orbital Surgery
    Livonia, Michigan 48152, United States
  • Washington University in St. Louis/Barnes Jewish Hospital
    Creve Coeur, Missouri 63141, United States
  • Columbia University
    New York, New York 10032, United States
  • Wake Forest Baptist Health Eye Center
    Winston-Salem, North Carolina 27157, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Neuro-Eye Clinical Trials, Inc.
    Bellaire, Texas 77401, United States
  • Eyelid Center of Utah
    Salt Lake City, Utah 84102, United States
  • West Virginia University Eye Institute
    Morgantown, West Virginia 26506, United States
  • Vancouver Coastal Health Eye Care Center
    Vancouver, British Columbia V5Z 3N9, Canada
  • Toronto Retina Institute
    North York, M3C 0G9, Canada
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Endocrinology Pawilione Zonda
    Milan, Italy
  • AOU Pisana
    Pisa, Italy
  • University of Pisa
    Pisa, Italy
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Hospital La Princesa
    Madrid, 28006, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Frimley Health Foundation Trust
    Camberley, GU16 7UJ, United Kingdom
  • Cardiff University
    Cardiff, CF14 4XN, United Kingdom
  • Moorfields Eye Hospital NIHR Clinical Research Facility
    London, EC1V 2PD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All individual participant data collected during the trial, after deidentification will be made available.

Supporting information: Study protocol

Time frame: Beginning 3 months and ending 5 years following article publication.

Access criteria: Proposals should be directed to info@slingtx.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Oct 2024, 27 months.

Results were first posted in Aug 2026, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2022
First posted
Mar 11, 2022
StartActual
Jul 1, 2022
Primary completionActual
Oct 15, 2024
CompletionActual
Sep 26, 2025
Results first posted
Aug 26, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05276063
Lead sponsor
Sling Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 11, 2022
Start date
Jul 1, 2022
Primary completion
Oct 15, 2024
Completion
Sep 26, 2025
Results posted
Aug 26, 2026
Last update
Sep 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linsitinib

Start the discussion